Modus Therapeutics Holding AB (99Z) Price & Analysis

0 Followers

99Z Stock Chart & Stats

€0.03

>-€0.01(-1.57%)

At close: Jan 08 4:00 PM EST

€0.03

>-€0.01(-1.57%)

Day’s Range― - ―

52-Week Range€0.01 - €0.33

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€3.93M

Enterprise Value€29.19

Total Cash (Recent Filing)€6.93M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding121,628,494

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageReported zero debt across 2023–2025 gives the company durable financial flexibility; low leverage reduces default risk and preserves optionality for strategic funding choices (equity, partnerships, or grants) during long clinical development cycles typical in biotech.

Focused Therapeutic StrategyA clear, concentrated pipeline targeting sickle cell disease is a structural strength: it aligns R&D resources to a high unmet medical need. Success would address a defined market and can attract targeted partnerships, orphan incentives, and specialist investors over the medium term.

Lean Operating StructureA very small headcount suggests a lean operating model that can extend cash runway by minimizing fixed overhead and relying on CROs and partnerships for trials. This cost discipline is durable while the company advances clinical programs and conserves limited capital.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flows, worsening to ~-SEK 18.1m in 2025, create ongoing financing requirements. Over 2–6 months this structural cash burn limits strategic optionality, increases financing urgency, and elevates execution risk absent clear new funding sources.

Pre-revenue ProfileNo revenue from 2020–2025 and recurring operating losses (net loss ~-SEK 18.5m in 2025) indicate revenue visibility is minimal. This pre-revenue status structurally constrains ability to self-fund development and means value depends heavily on clinical milestones and external financing.

Financing Dependence And Dilution RiskVolatile equity and absence of internal cash generation point to reliance on external capital raises. Over time this increases dilution risk and can pressure strategic choices, as management may prioritize near-term financing outcomes over long-term value-maximizing development decisions.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.33 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €3.93M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 27 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on May 26, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.